NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy

Lin, Tongtong; Hu, Liang; Hu, Fan; Li, Kun; Wang, Chao-Yu; Zong, Li-Juan; Zhao, Ya-Qian; Zhang, Xiaotao; Li, Yan; Yang, Yang; Wang, Yu; Jiang, Chun-Yi; Wu, Xuefeng; Liu, Wentao

doi:10.1158/2326-6066.cir-22-0197

Cited by 19 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, intraarticular injection NETs reduced the mechanical threshold in mice and joint hyperalgesia induced by NETs was prevented in mice deficient for Tlr 4 and Tlr 9 [ 63 ]. Moreover, eicosapentaenoic acid alleviated the hyperalgesia in oxaliplatin-induced peripheral neuropathy mice by inhibiting NETs formation and then abolishing NLR family pyrin domain containing 3 (NLRP3) inflammasome activation [ 64 ]. Therefore, NETs triggered by IL-17 may cause hyperalgesia through Toll-like receptor (TLR)-4, TLR-9 or activation of NLRP3.…”

Section: Peripheral Mechanisms Of Il-17 In Pathological Painmentioning

confidence: 99%

Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain

Gao

et al. 2024

View full text Add to dashboard Cite

Pathological pain imposes a huge burden on the economy and the lives of patients. At pre- sent, drugs used for the treatment of pathological pain have only modest efficacy and are also plagued by adverse effects and risk for misuse and abuse. Therefore, understanding the mechanisms of patho- logical pain is essential for the development of novel analgesics. Several lines of evidence indicate that interleukin-17 (IL-17) is upregulated in rodent models of pathological pain in the periphery and central nervous system. Besides, the administration of IL-17 antibody alleviated pathological pain. Moreover, IL-17 administration led to mechanical allodynia which was alleviated by the IL-17 antibody. In this review, we summarized and discussed the therapeutic potential of targeting IL-17 for pathological pain. The upregulation of IL-17 promoted the development of pathological pain by promoting neuroin- flammation, enhancing the excitability of dorsal root ganglion neurons, and promoting the communi- cation of glial cells and neurons in the spinal cord. In general, the existing research shows that IL-17 is an attractive therapeutic target for pathologic pain, but the underlying mechanisms still need to be in- vestigated.

show abstract

Section: Peripheral Mechanisms Of Il-17 In Pathological Painmentioning

confidence: 99%

Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain

Gao

et al. 2024

View full text Add to dashboard Cite

show abstract

“…Although so far, little evidence is available to investigate the relations between NETs and inflammasome. However, it was recently reported that NETs could trigger the NLRP3 inflammasome activation and IL-18 secretion release during the occurrence of oxaliplatin-induced peripheral neuropathy (OIPN) via the induction of the LPS-toll-like receptor 4 (TLR4)-JNK pathway ( Lin et al, 2022 ). However, to further explore the crosstalk between NETs and inflammasome, more studies are demanded for investigation.…”

Section: Part I: Biological Features Of Netsmentioning

confidence: 99%

Neutrophil extracellular traps in central nervous system (CNS) diseases

Shao,

Jiang,

Zhao

et al. 2024

PeerJ

View full text Add to dashboard Cite

Excessive induction of inflammatory and immune responses is widely considered as one of vital factors contributing to the pathogenesis and progression of central nervous system (CNS) diseases. Neutrophils are well-studied members of inflammatory and immune cell family, contributing to the innate and adaptive immunity. Neutrophil-released neutrophil extracellular traps (NETs) play an important role in the regulation of various kinds of diseases, including CNS diseases. In this review, current knowledge on the biological features of NETs will be introduced. In addition, the role of NETs in several popular and well-studied CNS diseases including cerebral stroke, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and neurological cancers will be described and discussed through the reviewing of previous related studies.

show abstract

“…At the same time, the average urinary excretion rate of LBP in 24 hours was as high as 70%, suggesting that LBP is rapidly cleared by the kidneys, does not accumulate easily in the body, has a short duration of action, and has mild adverse reactions ( 21 ). LBP has no obvious nephrotoxicity, ototoxicity, or neurotoxicity, and has significantly less gastrointestinal toxicity ( 22 ).…”

Section: Introductionmentioning

confidence: 99%

A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial

Zheng¹,

Wang²,

Xu³

et al. 2023

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an optimized and improved derivative of paclitaxel with superior efficacy and fewer adverse reactions, and it is widely used in the treatment of advanced gastric cancer. However, there is a paucity of data regarding the safety and efficacy of nab-paclitaxel combined with oxaliplatin (LBP) and tegafur in the treatment of patients with advanced gastric cancer. Methods This analysis is a prospective, single-center, open-label, historically controlled real-world study designed to include 10 patients with advanced gastric cancer treated with nab-paclitaxel combined with LBP and tegafur gimeracil oteracil potassium. The primary and main efficacy outcomes are safety indicators, including the incidence of adverse drug reactions and adverse events (AEs), as well as the outliers of laboratory indicators and vital signs. The secondary efficacy outcomes are overall survival (OS), objective response rate (ORR), disease control rate (DCR), and proportion of dose suspensions, dose reductions and discontinuations. Discussion Based on the findings of previous studies, we wished to assess the safety and efficacy of nab-paclitaxel combined with LBP and tegafur in the treatment of advanced gastric cancer. The trial requires constant contact and monitoring. The purpose is to determine a superior protocol in terms of patient survival, and pathological and objective response. Trial Registration This trial has been registered with the Clinical Trial Registry: NCT05052931 (registration date: 2021/9/12).

show abstract

NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy

Cited by 19 publications

References 48 publications

Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain

Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain

Neutrophil extracellular traps in central nervous system (CNS) diseases

A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial

Contact Info

Product

Resources

About